Meeting
2022 ASCO Annual Meeting
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
Authors
Caicun Zhou
Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China
Caicun Zhou , Ziping Wang , Meili Sun , Lejie Cao , Zhiyong Ma , Rong Wu , Yan Yu , Wenxiu Yao , Si Sun , Jianhua Chen , Wu Zhuang , Jiuwei Cui , Xueqin Chen , You Lu , Chunhong Hu , Jingru Wang , Rumei Chen , Mengmeng Qin , Hao Wang , Jason Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03789604
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9027)
DOI
10.1200/JCO.2022.40.16_suppl.9027
Abstract #
9027
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2014 ASCO Annual Meeting
Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR).
First Author: Hiroshige Yoshioka
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu